Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
Robert L FerrisLisa LicitraJerome FayetteCaroline EvenGeorge BlumenscheinKevin J HarringtonJoel GuigayEverett E VokesNabil F SabaRobert HaddadShanmugasundaram RamkumarJeffery S RussellPeter BrossartMakato TaharaA Dimitrios ColevasFernando Concha-BenaventeMark LynchLi LiMaura L GillisonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Nivolumab appeared to improve efficacy versus IC regardless of prior cetuximab use, supporting its use in patients with R/M SCCHN with or without prior cetuximab exposure. The reduction in risk of death with nivolumab compared with IC was greater in patients without prior cetuximab exposure versus with prior cetuximab exposure.